The estimated Net Worth of Jack L Stahl is at least $2.42 Million dollars as of 12 October 2021. Mr. Stahl owns over 9,326 units of Catalent stock worth over $2,103,508 and over the last 21 years he sold CTLT stock worth over $0. In addition, he makes $314,975 as Lead Independent Director at Catalent.
Sign up
Mr. Stahl CTLT stock SEC Form 4 insiders trading
Jack has made over 4 trades of the Catalent stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 9,326 units of CTLT stock worth $556,109 on 12 October 2021.
The largest trade he's ever made was buying 250,000 units of Catalent stock on 7 August 2006 worth over $247,500. On average, Jack trades about 16,519 units every 219 days since 2003. As of 12 October 2021 he still owns at least 35,276 units of Catalent stock.
You can see the complete history of Mr. Stahl stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jack Stahl biography
Jack L. Stahl is Lead Independent Director of the Company. Mr. Stahl was the President and Chief Executive Officer of Revlon, Inc. from 2002 until his retirement in 2006. Prior to joining Revlon, Mr. Stahl served as President and Chief Operating Officer of The Coca-Cola Company from 2000 to 2001, having previously served in various management positions since joining the company in 1979. Mr. Stahl serves on the boards of United Natural Foods, Inc. and Advantage Solutions LLC and on the U.S. board of advisors of CVC Capital. Additionally, Mr. Stahl formerly served on the boards of Schering-Plough Corporation, Dr Pepper Snapple Group, Saks, Inc., Coty Inc., and Royal Ahold Delhaize, and was chairman of the board of managers of New Avon LLC. Mr. Stahl holds a bachelor’s degree in economics from Emory University and a master’s degree from the Wharton School of Business at the University of Pennsylvania.
What is the salary of Jack Stahl?
As the Lead Independent Director of Catalent, the total compensation of Jack Stahl at Catalent is $314,975. There are 11 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
How old is Jack Stahl?
Jack Stahl is 66, he's been the Lead Independent Director of Catalent since 2016. There are 3 older and 24 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
What's Jack Stahl's mailing address?
Jack's mailing address filed with the SEC is 313 IRON HORSE WAY, , PROVIDENCE, RI, 02908.
Insiders trading at Catalent
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius, and Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
What does Catalent do?
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
What does Catalent's logo look like?
Complete history of Mr. Stahl stock trades at United Natural Foods, Catalent, Coty Inc, and Revlon
Catalent executives and stock owners
Catalent executives and other stock owners filed with the SEC include:
-
John Chiminski,
Chairman of the Board, Chief Executive Officer -
Peter Buzy,
Chairman - Gene Therapy -
Alessandro Maselli,
Pres & COO -
John R. Chiminski,
Chairman & CEO -
Alessandro Maselli,
President, Chief Operating Officer -
Jonathan Arnold,
President - Oral Drug Delivery Solutions -
Wetteny Joseph,
Chief Financial Officer, Senior Vice President -
Steven Fasman,
Senior Vice President, General Counsel and Corporate Secretary -
Steven L. Fasman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Karen A. Flynn,
Chief Commercial Officer -
Thomas P. Castellano,
Sr. VP & CFO -
Jack Stahl,
Lead Independent Director -
John Greisch,
Independent Director -
Donald Morel,
Independent Director -
Gregory Lucier,
Independent Director -
Rosemary Crane,
Independent Director -
Rolf Classon,
Independent Director -
J. Martin Carroll,
Independent Director -
Christa Kreuzburg,
Independent Director -
Madhavan Balachandran,
Independent Director -
Peter Zippelius,
Independent Director -
Z Mahdavi,
Vice President of Open Innovation, Biologics, Cell and Gene Therapy -
Jim Walter,
Vice President of Operations for its Oral and Specialty Delivery business -
Scott Gunther,
Senior Vice President - Quality & Regulatory Affairs -
Mike Grippo,
Senior Vice President - Strategy and Corporate Development -
Charles Lickfold,
Senior Vice President, Chief Information Officer -
Ricardo Pravda,
Chief Human Resource Officer, Senior Vice President -
Ricci Whitlow,
President - Clinical Supply Services -
Aristippos Gennadios,
President - Softgel Technologies -
Mario Gargiulo,
Region President, Biologics – Europe -
Karen Flynn,
President - Biologics and Chief Commercial Officer -
Manja Boerman,
President - Cell & Gene Therapy -
Ricardo Pravda,
Sr. VP & Chief HR Officer -
Michael J. Grippo,
Sr. VP of Strategy & Corp. Devel. -
Paul Surdez,
VP of Investor Relations -
Julien Meissonnier,
VP & Chief Scientific Officer -
Ricky Hopson,
VP & Chief Accounting Officer -
Sharon Johnson,
See Remarks -
Uwe Roehrhoff,
Director -
James Quella,
Director -
Management Associates V L.L...,
-
Melvin D Booth,
Director -
Matthew M Walsh,
See Remarks -
Christine Dolan,
See Remarks -
Stephen Leonard,
See Remarks -
Michael J Grippo,
SVP, Strategy & Corp. Dev. -
William Downie,
See Remarks -
Lance Miyamoto,
See Remarks -
Barry Littlejohns,
President, Biologics & SDD -
Paul W Jr Hegwood,
President, CSS -
Scott Houlton,
See Remarks -
Healthcare Partners L.L.C. ...,
10% owner -
Nielsen Kurt,
See Remarks -
Michael J Barber,
Director -
Michael Hatzfeld,
Chief Accounting Officer -
Thomas P Castellano,
SVP, Chief Financial Officer -
Frank A Damelio,
Director -
Michelle R Ryan,
Director -
Stephanie Okey,
Director -
Thomas W Hawkeswood,
Pres. Pharma Prod Delivery Div -
Karen Murphy Santiago,
VP & Chief Accounting Officer -
Patricia Hunt,
Pres. Consumer Health Div -
Michael A. Riley,
Pres. Bio Product Delivery Div -
Lorenzo Carletti,
SVP Global Ops Ph & Cons Hlth -
Kay A Schmidt,
SVP, Enterprise Functions -
Lisa Evoli,
SVP, Chief HR Officer -
Matti Masanovich,
SVP, Chief Financial Officer -
Ricardo Zayas,
SVP, Operations, Biologics NA -
Joseph Anthony Ferraro,
SVP, General Counsel, CCO -
Steven Barg,
Director -
David Mc Erlane,
Group President, Biologics -
Ricky Hopson,
Pres. BioProduct Delivery, CoS